Bristol-Myers Squibb Company (BMY)
NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
61.33-0.77 (-1.24%)
At close: 4:00PM EST
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 62.10 |
| Open | 62.03 |
| Bid | 61.06 x 900 |
| Ask | 61.72 x 800 |
| Day's Range | 61.26 - 62.70 |
| 52 Week Range | 45.76 - 67.16 |
| Volume | 13,229,819 |
| Avg. Volume | 11,960,785 |
| Market Cap | 137.409B |
| Beta (5Y Monthly) | 0.62 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.99 |
| Earnings Date | May 05, 2021 - May 10, 2021 |
| Forward Dividend & Yield | 1.96 (3.20%) |
| Ex-Dividend Date | Dec 31, 2020 |
| 1y Target Est | 75.13 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
View moreRelated Research
- Zacks
Agios' (AGIO) Q4 Loss In Line, Revenues Surpass Estimates
Agios' (AGIO) loss meets estimates in the fourth quarter of 2020 while revenues beat the same. Sale of leukemia drug, Tibsovo, rise both sequentially as well as year over year. Shares down.
- Investor's Business Daily
Is Bristol Myers Stock A Buy As Shares Flounder After Fourth-Quarter Beat?
Bristol Myers Squibb topped fourth-quarter expectations in February and cancer drug Opdivo returned to growth. But BMY stock floundered following the report. Is Bristol Myers stock a buy?
- Business Wire
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) in Combination with Cabometyx® (cabozantinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
BMS Receives Positive CHMP Opinion for Opdivo® in Combination with Cabometyx® as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
© 2021 Verizon Media. All rights reserved.
